MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyaf338

Медицинская библиотека · The oncologist · 2025

Molecular and clinical correlates of high FOLH1 (PSMA) RNA expression in primary and metastatic prostate cancer.

McKay Rana R, Nazari Shayan S, Elliott Andrew, Ribeiro Jennifer R, Rose Brent S, Barata Pedro C, Kilari Deepak, Garje Rohan, Agarwal Neeraj, Smith Norm, Antonarakis Emmanuel S, Bagrodia Aditya, Beltran Himisha

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Prostate-specific membrane antigen (PSMA; FOLH1) is a cell-surface target for diagnostics and treatment in prostate cancer. We utilized a database of molecularly-profiled prostate tumors to evaluate clinical, genomic, and immunologic correlates of high FOLH1 RNA expression.

PATIENTS AND

METHODS

Prostate cancer specimens (N = 7,082) underwent DNA/RNA sequencing and immunohistochemistry at Caris Life Sciences. FOLH1-High/Low expression was defined by upper/lower quartiles or median transcripts per million. Overall survival (OS) was calculated from insurance claims.

RESULTS

Prostate adenocarcinoma had 2.97-fold higher FOLH1 expression compared to high-grade neuroendocrine prostate cancer (q < 0.0001). Of 7,020 adenocarcinomas, 4,464 were primary prostate samples, 828 were lymph node metastases, and 1,686 were distant metastases. FOLH1 expression varied across metastatic sites (highest in lymph node and lowest in liver; 1.2-fold difference, q < 0.05). FOLH1-High tumors were enriched in AR-V7 variants (10.1% vs 4.5%, q < 0.05) and associated with higher androgen receptor (AR) signaling (0.82 vs 0.78, q < 0.05). Conversely, FOLH1-Low tumors were enriched with FOXA1 (12.2% vs 6.4%), APC (11.4% vs 3.0%), PIK3CA (5.8% vs 2.7%), and PIK3R1 (2.6% vs 0.48%) mutations (q < 0.05). FOLH1-High tumors had a lower M1:M2 ratio, fewer Tregs and CD8+ T cells, higher immune checkpoint expression, and lower interferon signature scores. FOLH1-High primary tumors were more frequently microsatellite instability-High, tumor mutational burden-High, and PD-L1-positive. Among patients with metastatic tumors, median OS was improved in the FOLH1-High group (31.9 vs 23.3 months, P < .001).

CONCLUSIONS

This enhanced understanding of the distinct molecular and clinical profiles of FOLH1-expressing prostate cancers may inform optimization of PSMA-directed treatments.

Для цитирования: McKay Rana R, Nazari Shayan S, Elliott Andrew, Ribeiro Jennifer R, Rose Brent S, Barata Pedro C, Kilari Deepak, Garje Rohan, Agarwal Neeraj, Smith Norm, Antonarakis Emmanuel S, Bagrodia Aditya, Beltran Himisha. Molecular and clinical correlates of high FOLH1 (PSMA) RNA expression in primary and metastatic prostate cancer.. The oncologist. 2025. DOI: 10.1093/oncolo/oyaf338.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.